| 1.67 0.04 (2.45%) | 10-15 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.21 | 1-year : | 2.59 |
| Resists | First : | 1.89 | Second : | 2.21 |
| Pivot price | 1.67  |
|||
| Supports | First : | 1.36 | Second : | 1.02 |
| MAs | MA(5) : | 1.68  |
MA(20) : | 1.62 |
| MA(100) : | 1.15 |
MA(250) : | 0.92 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 46.3 |
D(3) : | 54.4 |
| RSI | RSI(14): 59.1 |
|||
| 52-week | High : | 1.89 | Low : | 0.51 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ OCGN ] has closed above bottom band by 49.4%. Bollinger Bands are 42.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 20 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.72 - 1.73 | 1.73 - 1.74 |
| Low: | 1.6 - 1.61 | 1.61 - 1.62 |
| Close: | 1.66 - 1.67 | 1.67 - 1.68 |
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
Mon, 13 Oct 2025
Ocugen Stock Shock: What’s Next? - StocksToTrade
Sat, 27 Sep 2025
Ocugen (OCGN): Revisiting Valuation After New Kwangdong Licensing Deal and Pipeline Progress - simplywall.st
Tue, 23 Sep 2025
Ocugen: A Retinal Disease Juggernaut In The Making (NASDAQ:OCGN) - Seeking Alpha
Sun, 21 Sep 2025
Why Ocugen (OCGN) Is Up 25.2% After Securing Korean Rights for Gene Therapy OCU400 - simplywall.st
Tue, 26 Aug 2025
Ocugen (OCGN) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Tue, 12 Aug 2025
Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants - Ocugen
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 312 (M) |
| Held by Insiders | 2.8794e+008 (%) |
| Held by Institutions | 1.4 (%) |
| Shares Short | 54,540 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.234e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 4.7 % |
| Return on Equity (ttm) | -73.6 % |
| Qtrly Rev. Growth | 4.75e+006 % |
| Gross Profit (p.s.) | 4.83 |
| Sales Per Share | -135.72 |
| EBITDA (p.s.) | -7.04286e+006 |
| Qtrly Earnings Growth | -0.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -52 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.02 |
| Price to Cash Flow | 701.39 |
| Dividend | 0 |
| Forward Dividend | 5.278e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|